Sistema de Salut de Catalunya
Institut Català de la Salut
[Estrada N] Myeloid Neoplasms Research Group, Josep Carreras Leukemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Spain. [Xicoy B, Garcia O, Marcé S, Cabezón M, Zamora L] Myeloid Neoplasms Research Group, Josep Carreras Leukemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Spain. Hematology Department, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Spain. [Beier F, Ventura Ferreira MS, Brümmendorf TH] Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, Uniklinik RWTH Aachen University, Germany. [Morales C] Core-Hematology Department, Clinical Laboratory ICS-Metropolitan Nord, Hospital Germans Trias i Pujol, Badalona, Spain. [Boqué C] Hematology Department, Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain. [Sagüés M] Department d’Hematologia, Institut Català d'Oncologia Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Vallansot R] Hematology Department, Institut Català d'Oncologia-Hospital Universitari Joan XXIII, Tarragona, Spain
Hospital Universitari de Girona Dr Josep Trueta
2023-03-22T13:01:01Z
2023-03-22T13:01:01Z
2021-11-30
Leucèmia mieloide crònica; Resposta a imatinib; Telòmer
Leucemia mieloide crónica; Respuesta a imatinib; Telómero
Chronic myelogenous leukemia; Imatinib; Telomere
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation approaches. Few biological factors at diagnosis have been associated with this level of response. Telomere length (TL) in peripheral blood cells of patients with CML has been related to disease stage, response to therapy and disease progression, but little is known about its role on DMR. In this study, we analyzed if age-adjusted TL (referred as "delta-TL") at diagnosis of chronic phase (CP)-CML might correlate with the achievement of DMR under first-line imatinib treatment. TL from 96 CP-CML patients had been retrospectively analyzed at diagnosis by monochrome multiplex quantitative PCR. We observed that patients with longer age-adjusted telomeres at diagnosis had higher probabilities to achieve DMR with imatinib than those with shortened telomeres (P = 0.035 when delta-TL was studied as a continuous variable and P = 0.047 when categorized by the median). Moreover, patients carrying long telomeres also achieved major molecular response significantly earlier (P = 0.012). This study provides proof of concept that TL has a role in CML biology and when measured at diagnosis of CP-CML could help to identify patients likely to achieve DMR to first-line imatinib treatment.
This work was in part supported by a grant from Instituto de Salud Carlos III through the project “PI16/01200” (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/”Investing in your future”) as well as by the grant “Bolsa de ayuda económica para la innovación científica” and the grant “Becas de Investigación” both from Fundación Española de Hematología y Hemoterapia (FEHH). Figure 3. Cumulative incidence (95% CI) of MMR at 24 months from imatinib start. CI = confidence interval Downloaded from http://journals.lww.com/hemasphere by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCy wCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/
Article
Published version
English
Leucèmia mieloide crònica; Telòmer; Imatinib; DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Cycle::Cell Division::Telomere Homeostasis; CHEMICALS AND DRUGS::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva; FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::ciclo celular::división celular::homeostasis telomérica; COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::amidas::benzamidas::mesilato de imatinib
Lippincott, Williams & Wilkins
Hemasphere;5(12)
https://doi.org/10.1097/hs9.0000000000000657
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
